Skip to main content
European Commission logo print header

proactive monitoring of cancer as an alternative to surgery

Project description

Proactive cancer monitoring versus surgery

The original PRISAR consortium implemented an innovative approach using imaging technologies and hybrid fluorescence/radionuclide probes for surgical intervention in cancer treatment. That project resulted in the development of a hybrid probe for image-guided surgery as well as a variety of additional tools and instruments. Now, the EU-funded PRISAR2 project aims to continue this effort by developing new industrial monitoring technologies for the surveillance of cancer. This innovative imaging-based platform will increase the surveillance window to allow for optimal selection of treatment options over time, possibly avoiding surgery. The 'watch and wait' strategies will enable better study of the cancer's progression so that any risks to the patient can be minimised leading to a better clinical outcome.

Objective

From 2016 -2019, the “first” PRISAR consortium implemented the first Dutch RISE project of H2020 to investigate the use of imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. This PRISAR project provided a career-enabling human resource plethora of inter-disciplinary and inter-sectoral secondments, which resulted in the development, of not only a hybrid probe for image-guided surgery, but also a variety of tools and instruments. We now propose a new project, PRISAR2, to implement the next logical phase of this work, which is to clinically translate new and innovative monitoring technologies from industry. This will provide better patient selection and increase the surveillance window to allow for better treatment options over time and avoid surgery. This will involve developing new ‘watch and wait’ strategies to study the behaviour of the cancer so that any risks can be minimized. This would lead to a better clinical outcome and quality of life (QOL) for the patient and maximize the benefits of an active monitoring policy for both the patient and the healthcare system. When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Here, however, we aim to (a) develop new monitoring technologies from industry so that the surveillance window can be increased to allow for better treatment options over time and to avoid surgery, (b) develop new ‘watch and wait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to a better clinical outcome and (c) train a new generation of preclinical and clinical scientists to be able to implement this new concept as standard of care and to maximise the benefits of an active monitoring policy.

æ

Coordinator

PERCUROS BV

Participation ended

Net EU contribution
€ 331 200,00
Address
Eerbeeklaan 42
2573 HT 's-gravenhage (den haag)
Netherlands

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Zuid-Holland Agglomeratie ’s-Gravenhage
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 0,00

Participants (24)